4D Molecular Therapeutics, Inc.
FDMT
$9.48
-$0.39-3.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.40M | -56.88M | -54.66M | -47.97M | -49.67M |
| Total Depreciation and Amortization | 1.98M | 2.00M | 1.89M | 1.75M | 1.78M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.42M | 3.38M | 3.80M | 5.63M | 5.74M |
| Change in Net Operating Assets | 2.76M | 5.00M | 5.59M | -7.17M | -3.72M |
| Cash from Operations | 28.55M | -46.50M | -43.38M | -47.76M | -45.86M |
| Capital Expenditure | 70.00K | 91.00K | -66.00K | -631.00K | -949.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -128.92M | 17.69M | -13.79M | 32.58M | 8.01M |
| Cash from Investing | -128.85M | 17.78M | -13.85M | 31.95M | 7.06M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 111.98M | 116.00K | 862.00K | -- | 601.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 111.98M | 116.00K | 862.00K | -- | 601.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.69M | -28.60M | -56.37M | -15.81M | -38.20M |